Press releases

Filter by year:

GeNeuro to Present at 3rd 2019 HERVs & Disease International Workshop on Human Endogenous Retroviruses (HERVs) and Diseases

Geneva, Switzerland, October 31, 2019 – 7:30 am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, announced that the company will present at and sponsor the 3 rd HERVs & Disease International Workshop on Human Endogenous Retroviruses and Diseases, to be held November 5-6, 2019, in Lyon, France.

GeNeuro: financial information and business update for the third quarter 2019

Geneva, Switzerland, October 25, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes, reported today on its 2019 third quarter cash position and issued a business update.

GeNeuro Reports 2019 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, September 30, 2019 at 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported its half-year financial results for the period ending June 30, 2019 and provided a corporate update.

GeNeuro’s temelimab shows extended neuroprotective effects in relapsing-remitting MS

Geneva, Switzerland, September 16, 2019 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that the neuroprotective effects of temelimab in MS patients extend to 96 weeks and that it is safe to use and well tolerated for a prolonged period. These data, from ANGEL-MS, an extension of the Phase 2 CHANGE-MS trial in relapsing-remitting MS (RRMS), were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019) Congress in Stockholm, Sweden.

GeNeuro: financial information and business update for the second quarter 2019

Geneva, Switzerland, July 18, 2019, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 second quarter cash position and issued a business update.

PNAS publication supports temelimab’s rationale against neurodegeneration in MS

Geneva, Switzerland, June 26, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), is delighted to announce that data supporting the mode of action of its lead product (temelimab) in treating MS was published in the Proceedings of the National Academy of Sciences (PNAS). Temelimab is a monoclonal antibody designed to neutralize a pathogenic, viral envelope protein, pHERV-W Env, which plays a causal role in the development of MS.

GeNeuro Shareholders Approve all Proposals at AGM

Geneva, Switzerland, 3 June, 2019 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of 24 May, 2019.

GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results

Geneva, Switzerland, 7 May 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that a six-month extension of its Phase IIa study of temelimab (GNbAC1) in T1D confirmed all previouslyobserved positive observations in the trial, meeting its primary objective. GeNeuro believes these data open the door to further development in early-onset T1D pediatric patient population.

GeNeuro: Cash position at 31 March 2019 and Business Review

Geneva, Switzerland, April 24, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 first quarter cash position and issued a business update.

GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 1, 2019 –  GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2018 and provided a corporate update.


Results 1-10 of 12      Next Page      Last Page